IDO1 and non-small cell lung carcinoma: It is noteworthy that the degradation of EGFRL858R induced by compound 103 demonstrated significant suppression of programmed death receptor ligand 1 (PD-L1) and indoleamine-2,3-dioxygenase-1 (IDO1) levels in H3255 cells, which enhance anti-tumor immune response in NSCLC 92.